Classical biomedical simulation such that molecular dynamics, protein folding and in silico screening face significant limitations including scaling exponentially, crude approximations, and long simulation times. Since biological simulations are fundamentally quantum; classical models rely on crude approximations. Instead, quantum simulation brings to qubits a mapping of the systems of molecules, such that it is possible to compute their energetics and conformations with fidelity to physics. A hybrid digital pipeline with quantum techniques consists of uniting artificial intelligence (AI) with massive biomedical data warehousing, quantum-enhanced solvers compare interactions at the atomic scale, and results are reinvested in prioritization before anything is done in a wet lab. This review synthesizes the existing literature and summarizes the existing knowledge in the field of peer-reviewed articles as algorithms (e.g., VQE, annealing, QML), biomedical application (drug discovery, oncology, genomics, diagnostics), and results of the process (accuracy, runtime, cost, and reproducibility). The findings demonstrate an evident shift to hybrid quantum classical architectures that are more fidelity to modeling, less assays early stage due to virtual experimentation, and compress the research-to-treatment timeline claiming that quantum-AI is an emergent experimental basis of biomedicine.
Classical biomedical simulation such that molecular dynamics, protein folding and in silico screening face significant limitations including scaling exponentially, crude approximations, and long simulation times. Since biological simulations are fundamentally quantum; classical models rely on crude approximations. Instead, quantum simulation brings to qubits a mapping of the systems of molecules, such that it is possible to compute their energetics and conformations with fidelity to physics. A hybrid digital pipeline with quantum techniques consists of uniting artificial intelligence (AI) with massive biomedical data warehousing, quantum-enhanced solvers compare interactions at the atomic scale, and results are reinvested in prioritization before anything is done in a wet lab. This review synthesizes the existing literature and summarizes the existing knowledge in the field of peer-reviewed articles as algorithms (e.g., VQE, annealing, QML), biomedical application (drug discovery, oncology, genomics, diagnostics), and results of the process (accuracy, runtime, cost, and reproducibility). The findings demonstrate an evident shift to hybrid quantum classical architectures that are more fidelity to modeling, less assays early stage due to virtual experimentation, and compress the research-to-treatment timeline claiming that quantum-AI is an emergent experimental basis of biomedicine.
The convergence of quantum computing and artificial intelligence (AI) presents a paradigm shift in healthcare, revolutionizing complex biological simulations, genomic data processing, and drug discovery innovations. Traditional computational methods, despite their advancements, often struggle with the sheer scale and complexity of biological data, limiting the speed and accuracy of medical breakthroughs. Quantum computing, with its ability to process vast datasets exponentially faster than classical computers, coupled with AI's predictive capabilities, offers a transformative solution for accelerating biomedical research and clinical applications. This paper explores quantum machine learning’s role in optimizing AI-driven molecular dynamics simulations for drug discovery. By leveraging quantum-enhanced algorithms, researchers can rapidly model molecular interactions, analyze drug-receptor binding affinities, and predict pharmacokinetics with unprecedented precision. Additionally, we examine quantum-assisted deep learning models for deciphering intricate biological mechanisms such as protein folding, epigenetic modifications, and metabolic pathway interactions, enabling more accurate predictions of disease progression and therapeutic targets. Furthermore, the integration of AI-quantum hybrid models in clinical diagnostics and imaging analytics is redefining personalized medicine. Quantum-enhanced deep learning facilitates high-resolution medical imaging, real-time anomaly detection, and optimized radiomic feature extraction, leading to early and more accurate disease diagnosis. In genomics, quantum computing significantly accelerates whole-genome sequencing and mutation analysis, paving the way for tailored treatment strategies based on an individual's genetic profile. Despite its promise, challenges such as quantum hardware limitations, data coherence issues, and ethical considerations must be addressed to ensure the practical implementation of quantum-AI healthcare solutions. This paper provides a comprehensive analysis of the potential, challenges, and future directions of quantum-AI synergy in transforming modern healthcare.
The convergence of quantum computing and artificial intelligence (AI) presents a paradigm shift in healthcare, revolutionizing complex biological simulations, genomic data processing, and drug discovery innovations. Traditional computational methods, despite their advancements, often struggle with the sheer scale and complexity of biological data, limiting the speed and accuracy of medical breakthroughs. Quantum computing, with its ability to process vast datasets exponentially faster than classical computers, coupled with AI\\\'s predictive capabilities, offers a transformative solution for accelerating biomedical research and clinical applications. This paper explores quantum machine learning's role in optimizing AI-driven molecular dynamics simulations for drug discovery. By leveraging quantum-enhanced algorithms, researchers can rapidly model molecular interactions, analyze drug- receptor binding affinities, and predict pharmacokinetics with unprecedented precision. Additionally, we examine quantum-assisted deep learning models for deciphering intricate biological mechanisms such as protein folding, epigenetic modifications, and metabolic pathway interactions, enabling more accurate predictions of disease progression and therapeutic targets. Furthermore, the integration of AI-quantum hybrid models in clinical diagnostics and imaging analytics is redefining personalized medicine. Quantum-enhanced deep learning facilitates high-resolution medical imaging, real-time anomaly detection, and optimized radiomic feature extraction, leading to early and more accurate disease diagnosis. In genomics, quantum computing significantly accelerates whole-genome sequencing and mutation analysis, paving the way for tailored treatment strategies based on an individual\\\'s genetic profile. Despite its promise, challenges such as quantum hardware limitations, data coherence issues, and ethical considerations must be addressed to ensure the practical implementation of quantum-AI healthcare solutions.
Precision medicine aims to tailor healthcare by integrating individual genetic, epigenetic, transcriptomic, proteomic, and clinical data, collectively referred to as multi-omic data. However, the scale and complexity of such multi-omics datasets challenge classical computing approaches. Quantum computing, which leverages superposition and entanglement (quantum-level correlations between particles), offers a fundamentally new paradigm for accelerating molecular simulations, biomarker discovery, and high-dimensional data analysis. This review explores the convergence of quantum computing and it's potential to provide unmet needs in precision biomedicine research, with emphasis on applications in diagnostic modeling, multi-omic data integration and drug discovery. We highlight early proof-of-concept studies demonstrating the use of quantum machine learning for disease prediction, quantum algorithms for protein folding, and quantum generative models for novel drug design. Hybrid quantum-classical workflows are also already enabling gene network inference and prioritization of variants of uncertain significance, the latter of which is a major focus of multi-omic research worldwide. Emerging directions include digital twin simulations and real-time clinical decision support powered by quantum models. Looking ahead, the long-term vision for quantum computing in biomedicine involves in silico modeling of entire biological systems to simulate cellular responses to perturbations like drug treatments, enabling clinicians to test therapies in virtual patients before real-world application. Despite these advances, practical implementation remains limited by hardware constraints, qubit decoherence, algorithm scalability, and regulatory barriers. Nonetheless, as quantum hardware evolves and AI-aligned quantum algorithms mature, their integration holds transformative potential. Quantum computing may eventually shorten diagnostic timelines, improve therapeutic precision, and make biomedical innovation more globally accessible. We outline a roadmap for translating these technologies into next-generation precision medicine.
The integration of Artificial intelligence (AI) and Quantum computing (QC) is redefining the future of pharmaceutical research and development.While AI-particularly Machine learning (ML) and deep learning-accelerates target identification, virtual screening, and de novo drug design, it often suffers from interpretability issues, data bias, and limited mechanistic understanding.Conversely, QC leverages quantum mechanics to achieve unprecedented accuracy in molecular simulations, yet remains restricted by noise, limited qubits in the Noisy Intermediate-Scale Quantum (NISQ) era, and high costs.Emerging hybrid quantum-classical algorithms and Quantum Machine Learning (QML) approaches bridge these gaps, enabling high-fidelity in silico drug discovery workflows.Despite these advances, the regulatory environment has not kept pace.Current frameworks, such as Physiologically Based Pharmacokinetic (PBPK) modelling and Quantitative Structure-Activity Relationship (QSAR) models, provide limited guidance for validating complex AI-QC systems.Challenges include the lack of explainable artificial intelligence (XAI), uncertainty in verifying quantum outputs, data integrity, and accountability in hybrid pipelines.These gaps highlight the urgent need for regulatory science to adopt dynamic validation frameworks, algorithmic audits, and international harmonization.This review critically examines the technological and regulatory dimensions of AI-QC synergy in drug discovery, outlining key applications, limitations, and ethical considerations.We propose pathways for explainability-by-design, continuous learning oversight, and regulatory sandboxes to facilitate safe and effective adoption.The synergy of AI and QC offers the potential to accelerate timelines, reduce costs, and deliver precision medicines globally-but its promise can only be realized through proactive, transparent, and ethical governance.
With the growing complexity of biomedical data, molecular interactions and genomic architectures, there are significant challenges in adapting traditional healthcare analytics and drug discovery systems to meet computational demands. The paradigm of quantum computing has recently come into the spotlight as a potential method to solve multidimensional optimization, molecular simulation and genomic inference problems using concepts like superposition, entanglement, and quantum parallelism. This chapter examines quantum algorithms and hybrid quantum-classical architectures in the drug discovery, protein folding, genomic analysis, and precision medicine applications. It also explores quantum machine learning algorithms such as VQE, QAOA, QSVM, and QNN, which are used for intelligent biomedical analytics. In addition, the conversation also covers cloud-edge quantum healthcare infrastructures, post-quantum security, and real-world healthcare applications, further demonstrating the potential impact of quantum-enhanced healthcare systems.
Artificial Intelligence (AI) and Quantum Computing together are going to transform medical research, diagnostics and the simulation of treatment. Although it has already been applied to medical imaging, drug discovery and predictive analytics, AI needs large amounts of computations that are sometimes beyond the capacity of more traditional computing. Quantum computers due to their capability to do parallel processing over quantum states can be fast and efficient in unprecedented ways. The paper will discuss the combination of AI and quantum computing in the medical field, including the characterization of medical applications of AI where it complements quantum computing, an overview of the current medical applications of AI and quantum computing, and real-time diagnostics, genomics, drug discovery, molecular dynamics, and personalized medicine. We discuss the current issues state-of-art including quantum error correction, interpretability of models, and ethical implications and point toward future opportunities including digital twins, federated learning using quantum resources, and hybrid quantum-classical models. The eventuality of this integration might end up speeding up medical simulations, decreasing the expense of drug development and enhancing the patient outcomes across the globe.